Showing 1541-1550 of 6808 results for "".
My Lumixyl Experience
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/my-lumixyl-experience/19444/A patient of Dr. Ashish Bhatia's, describes her experience using Lumixyl Brightening System for her adult acne.Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Differentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of itsJournal Club: A Comprehensive Update
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-a-comprehensive-update/32402/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses the recent Lancet article "Atopic Dermatitis" with primary author Emma Guttman, MD, PhD. Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583-596. doi: 10.1016/S0140-6736(24)0SCALE 2024: Dr. Michelle Henry on Innovative Skincare Products and Lasers in Skin of Color
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michelle-henry-innovative-skincare-products-and-lasers-skin-color/26374/Michelle Henry, MD, discusses innovative skincare products and lasers in skin of color, including her top 10 tips for ensuring best outcomes and reducing adverse events, at Music City SCALE.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.Achieve Skin Tightening in 1-2-3
https://practicaldermatology.com/conferences/maui-derm-2024/achieve-skin-tightening-in-1-2-3/20239/Mitchel P. Goldman, MD, Founder and Medical Director, Cosmetic Laser Dermatology, and Medical Director, Platinum Dermatology Partners, explains the three basic technologies he swears by to tighten skin.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisFDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.DermWireTV: The Year in Review - 2023!
https://practicaldermatology.com/topics/psoriasis/dermwiretv-the-year-in-review-2023/20229/Practical Dermatology® Co-Chief Medical Editor, Joel Schlessinger, MD, shares his thoughts on some of the best products and approvals of 2023 as well as the potential of new JAK inhibitors to treat alopecia areata, vitiligo, psoriasis, and atopic dermatitis. Our new contributor, Andrew Mastro, PA, t